Insider buying last 90 days
No open-market insider purchases were filed for LGND in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Ligand Pharmaceuticals draws attention this week as an insider sale and two Form 144 filings sit alongside continued commentary on the company's growth story. An analyst piece points to Filspari's 85% year-over-year royalty growth and the new FSGS indication as the lead earnings driver, while XOMA's $12.3 million Q3 royalty contribution is cited as adding diversification and pipeline depth, with a BUY rating attached to that view.
Shares close at $314.15, up 2.6%, sitting above both the 50-day average of $299.49 and the 200-day average of $255.99, with the 50-day above the 200-day. The GekkoIndex reads 56.2, placing LGND in the Neutral zone, up 2.1 over five sessions. Price stands 9.2% above Gekko Fair Value of $287.79. The one-year return is 50.9%, with 42.5% over six months and 4.1% over the past month, against a 52-week range of $175.89 to $326.63.
The next earnings report is scheduled for 25 February 2027, 107 days out, placing it beyond a typical 20-trading-day stretch; the prior report on 6 August 2026 showed EPS of $2.37 against a $2.01 estimate, with a -3.1% reaction. Seasonality over five years shows an average 20-day gain of 3.5% from this point, rising in 4 of those years. No insider, Congress or unusual options activity is recorded in their respective windows, leaving the consensus among 9 covering firms, all rated buy with a $350.92 target, as the notable external marker to watch.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Ligand Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
Above 50 and 200-day
Close $308.79 is above the 50-day ($301.71) and 200-day ($258.37) averages, and the 50-day is above the 200-day.
See the chart57, Neutral
Reading 57 is in the Neutral zone.
See the GekkoIndex4.7% above
Price is within 5% of Gekko Fair Value (4.7% above).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earnings−5.0% on average
From this point in the calendar, the next 20 trading days averaged −5% over 5 years, rising in 1 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Ligand Pharmaceuticals closed at $308.79 on Nov 13, 2026, +50.2% over the past year, inside a 52-week range of $175.89 to $326.63.
Use the left and right arrow keys to read daily values.
Put LGND on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Ligand Pharmaceuticals works with drugmakers around the world, supplying technologies and materials that support the discovery and development of new medicines. The company is closely associated with Captisol, a proprietary formulation technology it supplies directly and which underpins several products used across its partnerships. Its name is tied to treatments spanning blood cancers, infectious disease, bone health and other conditions, reflecting the breadth of the therapies it has helped bring to market.
Ligand's commercialized products cover a wide medical range, including therapies for multiple myeloma and leukemia, COVID-19 and pneumococcal disease, osteoporosis, postpartum depression, autoimmune disorders, breast cancer and hypertension, among others. Beyond these marketed products, the company takes part in numerous partnered programs still in clinical development, addressing cancer, seizure disorders, diabetes, cardiovascular disease, muscle wasting, and hepatic and renal conditions. Its role centers on enabling other pharmaceutical companies' research and product development rather than solely marketing medicines under its own name.
Founded in 1987, Ligand Pharmaceuticals is based in Emeryville, California. Its shares trade on the NASDAQ under the ticker LGND.
Ligand Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, down 0.9 points over five sessions.
Down 0.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 2 | Too few readings yet | |||
| Accumulation | 163 | +2.5% | +8.5% | ||
| Neutral (current zone) | 452 | +0.9% | +3.8% | ||
| Distribution | 75 | −0.2% | +2.4% | ||
| Selling | 10 | +1.6% | −2.0% | ||
Average LGND share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Ligand Pharmaceuticals trades 4.7% above Gekko Fair Value of $294.94, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Ligand Pharmaceuticals shares are worth, recalculated every trading day.
$294.94
Gekko Fair Value, Nov 14, 2026
4.7% above fair value · About fair value
At the end of Aug 2026 the price was 13.1% below the estimate.
No open-market insider purchases were filed for Ligand Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for LGND in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in LGND were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Ligand Pharmaceuticals has been buying back its own shares.
From company filings.
Ligand Pharmaceuticals reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | $2.37 est $2.01 | $63.69M est $61.30M | −3.1% |
| May 14, 2026 | $1.63 est $1.84 | $51.72M est $59.10M | −3.6% |
| Feb 26, 2026 | $2.02 est $1.46 | $59.67M est $55.59M | +3.6% |
| Nov 6, 2025 | $3.09 est $1.97 | $115.5M est $55.59M | +6.4% |
| Aug 7, 2025 | $1.60 est $1.42 | $47.63M est $43.87M | +5.4% |
| May 8, 2025 | $1.33 est $1.21 | $45.33M est $38.71M | −1.1% |
| Feb 27, 2025 | −$1.64 est $1.37 | $42.81M est $39.03M | +6.3% |
| Nov 7, 2024 | −$0.39 est $0.75 | $51.81M est $39.01M | +3.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Ligand Pharmaceuticals is $361.27, +17.0% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | H.C. Wainwright | $358 | +15.9% |
| Nov 11 | Barclays | $350 | +13.3% |
| Nov 5 | Citi | $402 | +30.2% |
| Nov 2 | Leerink Partners | $350 | +13.3% |
| Nov 1 | RBC Capital | $357 | +15.6% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Ligand Pharmaceuticals averaged −5.0% across the last 5 years, rising in 1 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.3% | 2 of 5 |
| Next 10 trading days | −2.2% | 2 of 5 |
| Next 15 trading days | −4.4% | 2 of 5 |
| Next 20 trading days | −5.0% | 1 of 5 |
| Next 30 trading days | −1.3% | 1 of 5 |
For scale, LGND’s typical 20-trading-day move in either direction is about 7.1%.
Ligand Pharmaceuticals’s market cap is $6.18B, with a P/E ratio of 127 and revenue of $253.8M over the last twelve months.
Coverage of Ligand Pharmaceuticals this week reads neutral: 0 positive, 3 neutral and 2 negative headlines.
Ligand Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 24.0% above |
| JNJJohnson & Johnson | Neutral | 4.4% above |
| ABBVAbbVie | Neutral | 23.7% above |
| MRKMerck | Neutral | 8.2% below |
| AZNAstraZeneca | Neutral | 34.6% below |
| PFEPfizer | Accumulation | 8.9% below |
A peer links to its own page where one exists.
Ligand Pharmaceuticals’s market cap is $6.18B at the Nov 13, 2026 close of $308.79, with 20.00M shares outstanding. The shares trade on a P/E ratio of 127.
The consensus analyst 12-month price target for Ligand Pharmaceuticals is $361.27, +17.0% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Ligand Pharmaceuticals is about fair value: the Nov 13, 2026 close of $308.79 is 4.7% above Gekko Fair Value of $294.94. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Ligand Pharmaceuticals is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of $2.84 per share on revenue of $97.80M. Ligand Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 4.2% on average across the report.
Ligand Pharmaceuticals’s 52-week high is $326.63 and its 52-week low is $175.89; it closed at $308.79 on Nov 13, 2026, +50.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and fair value) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.